Effectiveness of cetrorelix for the prevention of premature luteinizing hormone surge during controlled ovarian stimulation using letrozole and gonadotropins: a randomized trial

Tsung Hsien Lee, Yu Hung Lin, Kok Min Seow, Jiann-Loung Hwang, Chii Ruey Tzeng, Yu Shih Yang

研究成果: 雜誌貢獻文章

29 引文 (Scopus)

摘要

Objective: To evaluate the effectiveness of a GnRH antagonist in preventing premature LH surge under a letrozole and gonadotropin protocol. Design: Prospective, randomized clinical trial. Setting: A teaching hospital and tertiary medical center. Patient(s): Sixty-one patients were randomly assigned into two letrozole and gonadotropin-treated groups. These were distinguished by the absence (group I) or presence (group II) of supplementation with 0.25 mg of cetrorelix. Intervention(s): Controlled ovarian stimulation with letrozole and gonadotropins, cetrorelix and intrauterine insemination. Main Outcome Measure(s): Rate of premature LH surge. Result(s): Compared with group I, the rate of premature LH surge was statistically significantly lower for group II (43.4% [13/30] vs. 19.4% [6/31]), but the amount of gonadotropins used was statistically significantly higher (817.5 ± 28.5 vs. 907.5 ± 27.3 IU). Patients with premature LH surge had a statistically significantly lower pregnancy rate (21.4% [9/42] vs. 0 [0/18]) relative to their unaffected counterparts. Conclusion(s): A flexible protocol of 0.25 mg of cetrorelix for IUI cycles appears to suppress the rate of premature LH surge during ovarian stimulation with letrozole and gonadotropins. However, the incidence of premature LH surge remains too high, and modification will be necessary before the application of cetrorelix to IVF treatment.
原文英語
頁(從 - 到)113-120
頁數8
期刊Fertility and Sterility
90
發行號1
DOIs
出版狀態已發佈 - 七月 2008

指紋

letrozole
Ovulation Induction
Luteinizing Hormone
Gonadotropins
Insemination
Pregnancy Rate
Gonadotropin-Releasing Hormone
Teaching Hospitals
Randomized Controlled Trials
Outcome Assessment (Health Care)
cetrorelix

ASJC Scopus subject areas

  • Obstetrics and Gynaecology

引用此文

Effectiveness of cetrorelix for the prevention of premature luteinizing hormone surge during controlled ovarian stimulation using letrozole and gonadotropins : a randomized trial. / Lee, Tsung Hsien; Lin, Yu Hung; Seow, Kok Min; Hwang, Jiann-Loung; Tzeng, Chii Ruey; Yang, Yu Shih.

於: Fertility and Sterility, 卷 90, 編號 1, 07.2008, p. 113-120.

研究成果: 雜誌貢獻文章

@article{f9cfd8a653ae4feab172c780f25faf91,
title = "Effectiveness of cetrorelix for the prevention of premature luteinizing hormone surge during controlled ovarian stimulation using letrozole and gonadotropins: a randomized trial",
abstract = "Objective: To evaluate the effectiveness of a GnRH antagonist in preventing premature LH surge under a letrozole and gonadotropin protocol. Design: Prospective, randomized clinical trial. Setting: A teaching hospital and tertiary medical center. Patient(s): Sixty-one patients were randomly assigned into two letrozole and gonadotropin-treated groups. These were distinguished by the absence (group I) or presence (group II) of supplementation with 0.25 mg of cetrorelix. Intervention(s): Controlled ovarian stimulation with letrozole and gonadotropins, cetrorelix and intrauterine insemination. Main Outcome Measure(s): Rate of premature LH surge. Result(s): Compared with group I, the rate of premature LH surge was statistically significantly lower for group II (43.4{\%} [13/30] vs. 19.4{\%} [6/31]), but the amount of gonadotropins used was statistically significantly higher (817.5 ± 28.5 vs. 907.5 ± 27.3 IU). Patients with premature LH surge had a statistically significantly lower pregnancy rate (21.4{\%} [9/42] vs. 0 [0/18]) relative to their unaffected counterparts. Conclusion(s): A flexible protocol of 0.25 mg of cetrorelix for IUI cycles appears to suppress the rate of premature LH surge during ovarian stimulation with letrozole and gonadotropins. However, the incidence of premature LH surge remains too high, and modification will be necessary before the application of cetrorelix to IVF treatment.",
keywords = "Aromatase inhibitor, GnRH antagonist, ovulation induction, pregnancy, premature LH surge",
author = "Lee, {Tsung Hsien} and Lin, {Yu Hung} and Seow, {Kok Min} and Jiann-Loung Hwang and Tzeng, {Chii Ruey} and Yang, {Yu Shih}",
year = "2008",
month = "7",
doi = "10.1016/j.fertnstert.2007.06.029",
language = "English",
volume = "90",
pages = "113--120",
journal = "Fertility and Sterility",
issn = "0015-0282",
publisher = "Elsevier",
number = "1",

}

TY - JOUR

T1 - Effectiveness of cetrorelix for the prevention of premature luteinizing hormone surge during controlled ovarian stimulation using letrozole and gonadotropins

T2 - a randomized trial

AU - Lee, Tsung Hsien

AU - Lin, Yu Hung

AU - Seow, Kok Min

AU - Hwang, Jiann-Loung

AU - Tzeng, Chii Ruey

AU - Yang, Yu Shih

PY - 2008/7

Y1 - 2008/7

N2 - Objective: To evaluate the effectiveness of a GnRH antagonist in preventing premature LH surge under a letrozole and gonadotropin protocol. Design: Prospective, randomized clinical trial. Setting: A teaching hospital and tertiary medical center. Patient(s): Sixty-one patients were randomly assigned into two letrozole and gonadotropin-treated groups. These were distinguished by the absence (group I) or presence (group II) of supplementation with 0.25 mg of cetrorelix. Intervention(s): Controlled ovarian stimulation with letrozole and gonadotropins, cetrorelix and intrauterine insemination. Main Outcome Measure(s): Rate of premature LH surge. Result(s): Compared with group I, the rate of premature LH surge was statistically significantly lower for group II (43.4% [13/30] vs. 19.4% [6/31]), but the amount of gonadotropins used was statistically significantly higher (817.5 ± 28.5 vs. 907.5 ± 27.3 IU). Patients with premature LH surge had a statistically significantly lower pregnancy rate (21.4% [9/42] vs. 0 [0/18]) relative to their unaffected counterparts. Conclusion(s): A flexible protocol of 0.25 mg of cetrorelix for IUI cycles appears to suppress the rate of premature LH surge during ovarian stimulation with letrozole and gonadotropins. However, the incidence of premature LH surge remains too high, and modification will be necessary before the application of cetrorelix to IVF treatment.

AB - Objective: To evaluate the effectiveness of a GnRH antagonist in preventing premature LH surge under a letrozole and gonadotropin protocol. Design: Prospective, randomized clinical trial. Setting: A teaching hospital and tertiary medical center. Patient(s): Sixty-one patients were randomly assigned into two letrozole and gonadotropin-treated groups. These were distinguished by the absence (group I) or presence (group II) of supplementation with 0.25 mg of cetrorelix. Intervention(s): Controlled ovarian stimulation with letrozole and gonadotropins, cetrorelix and intrauterine insemination. Main Outcome Measure(s): Rate of premature LH surge. Result(s): Compared with group I, the rate of premature LH surge was statistically significantly lower for group II (43.4% [13/30] vs. 19.4% [6/31]), but the amount of gonadotropins used was statistically significantly higher (817.5 ± 28.5 vs. 907.5 ± 27.3 IU). Patients with premature LH surge had a statistically significantly lower pregnancy rate (21.4% [9/42] vs. 0 [0/18]) relative to their unaffected counterparts. Conclusion(s): A flexible protocol of 0.25 mg of cetrorelix for IUI cycles appears to suppress the rate of premature LH surge during ovarian stimulation with letrozole and gonadotropins. However, the incidence of premature LH surge remains too high, and modification will be necessary before the application of cetrorelix to IVF treatment.

KW - Aromatase inhibitor

KW - GnRH antagonist

KW - ovulation induction

KW - pregnancy

KW - premature LH surge

UR - http://www.scopus.com/inward/record.url?scp=45849141630&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=45849141630&partnerID=8YFLogxK

U2 - 10.1016/j.fertnstert.2007.06.029

DO - 10.1016/j.fertnstert.2007.06.029

M3 - Article

C2 - 18054932

AN - SCOPUS:45849141630

VL - 90

SP - 113

EP - 120

JO - Fertility and Sterility

JF - Fertility and Sterility

SN - 0015-0282

IS - 1

ER -